Glenmark Life Sciences IPO – Competitive Strengths, Key Risks, Concerns: ICICI Direct

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Research’s IPO Report

Glenmark Life Sciences is an active pharmaceutical ingredients arm of Glenmark Ltd.

Glenmark commenced the API manufacturing business by setting up a manufacturing facility in Kurkumbh, Maharashtra in 2001-02. In 2019, the API manufacturing business was spun off into Glenmark API.

Currently, it has four manufacturing facilities at Ankaleshwar, Dahej in Gujarat and Mohol, Kurkumbh in Maharashtra with total installed capacity of 726.6 kiloliter as of FY21.

Revenues from regulated markets were 65.64% of FY21 revenues.

As of FY21, Glenmark Life Sciences had a portfolio of 120 molecules globally, sold APIs in India and exported APIs to multiple countries in Europe, U.S., Latin America, Japan and rest of world.

As of May 31, 2021, it had filed 403 drug master files and certificate of suitabilities.

Click on the attachment to read the full IPO report:

ICICI Direct Glenmark Life IPO Review.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button